Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Finished Goods (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Finished Goods for 6 consecutive years, with $11.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods fell 22.78% year-over-year to $11.5 million, compared with a TTM value of $11.5 million through Dec 2025, down 22.78%, and an annual FY2025 reading of $11.5 million, down 22.78% over the prior year.
  • Finished Goods was $11.5 million for Q4 2025 at Cytek Biosciences, down from $20.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $22.8 million in Q1 2023 and bottomed at $9.1 million in Q2 2021.
  • Average Finished Goods over 5 years is $15.4 million, with a median of $15.2 million recorded in 2025.
  • The sharpest move saw Finished Goods surged 86.31% in 2022, then crashed 34.36% in 2024.
  • Year by year, Finished Goods stood at $12.6 million in 2021, then increased by 29.48% to $16.3 million in 2022, then dropped by 9.96% to $14.7 million in 2023, then increased by 0.88% to $14.8 million in 2024, then decreased by 22.78% to $11.5 million in 2025.
  • Business Quant data shows Finished Goods for CTKB at $11.5 million in Q4 2025, $20.3 million in Q3 2025, and $16.9 million in Q2 2025.